Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors.

ABSTRACT:

Background

As the objective overall response rate to immune checkpoint inhibitors (ICIs) is less than 30% in late stage or metastatic bladder cancer (BLCA), elucidating the intrinsic mechanisms of immune evasion is of great importance for the discovery of predictive and prognostic biomarkers and the exploration of novel targets for intervention. Recent studies have shown that OBSCN and the cytoskeletal protein it encodes, obscurin, play an important role in tumour progression. However, no studies have reported the role of OBSCN in BLCA.

Methods

RNA sequencing and clinical data were downloaded from multiple public databases including The Cancer Genome Atlas and the Gene Expression Omnibus. Immunohistochemistry (IHC) was performed on tissue microarrays including 80 BLCA patien

SUBMITTER: Wang T 

PROVIDER: S-EPMC11948897 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature